MedTrace Logo

A Study to Evaluate Single Doses of Alpha-0261 in Healthy Adult Volunteers

NCT07279636 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-12-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Alpha-0261 tablets after single oral administration in healthy adult volunteers.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Alpha-0261

Oral, tablet

OTHER

Placebo

Oral, tablet

Sponsors & Collaborators

  • AlphaMol Science Ltd. (Shanghai)

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-21
Primary Completion
2026-03-20
Completion
2026-05-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07279636 on ClinicalTrials.gov